Assessing Ionis Pharmaceuticals: Insights From 8 Financial Analysts
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $55.0, with a high ...
Le Lézard9h
LSL PHARMA GROUP APPOINTS LOUIS LAFLAMME TO THE BOARD OF DIRECTORS
LSL PHARMA GROUP INC. (the "Corporation" or "LSL Pharma"), a Canadian integrated pharmaceutical company, is pleased to ...
Le Lézard9h
BrainStorm Cell Therapeutics Announces Full Year 2024 Financial Results and Provides Corporate Update
BrainStorm Cell Therapeutics Inc. , a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the fiscal year ended December 31, 2024, ...
Ionis to present at upcoming investor conferences
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in fireside chats at the ...